85 WELLS AVENUE, NEWTON, MA
Karyopharm Therapeutics Closes Financing Transactions with Lenders
Karyopharm Strategic Financing Extends Cash Runway to Q2 2026
Changes in Board, Management or Compensation
Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
Investor Presentation
News
Earnings Release
Annual Report to Security Holders
Q2
Q1
FY 2023
Q3
Registration Statement for Securities to be Offered to Employees
SC TO-I
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Tender Offer Statement by Issuer
Correspondence